Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14985269 | 0.79 | KDM1A (0.34) | — | |
| SCHEMBL18491374 | 0.64 | PRKCI (0.49) | — | |
| SCHEMBL5036727 | 0.63 | — | — | |
| SCHEMBL23346675 | 0.63 | CCR9 (0.33) | — | |
| SCHEMBL4109131 | 0.63 | POLB (0.63) | — | |
| SCHEMBL2382637 | 0.61 | HTR2A (0.54) | — | |
| SCHEMBL14977330 | 0.61 | ASH1L (0.41) | ASH1L | |
| SCHEMBL14981465 | 0.61 | HTR2C (0.55) | ASH1L | |
| SCHEMBL20660559 | 0.60 | AR (0.32) | — | |
| SCHEMBL7952618 | 0.59 | SMN1; SMN2 (0.42) | ASH1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097758-B2 | Isoserine derivatives for use as coagulation factor IXa inhibitors | SANOFI-AVENTIS (FR) | 2012-01-17 | — | — | US | disclosed |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | TFPI, F2, F9 | ASH1L 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.